Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study

BMC Infectious Diseases

Nicola Low¹  Phillip Hay³  Sally Kerry²  Pippa Oakeshott⁴  Janneke CM Heijne¹  Christian L Althaus¹  Sereina A Herzog¹ 

[1] Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, CH-3012, Switzerland;Centre for Primary Care and Public Health, Blizard Institute, Queen Mary University of London, London, E12AB, UK;Department of Genitourinary Medicine, St George’s Hospital, London, SW17 0QT, UK;Division of Population Health Sciences and Education, St George’s, University of London, London, SW17 0RE, UK

关键词: Randomised controlled trials;    Compartmental model;    Mathematical model;    Pelvic inflammatory disease;    Chlamydia infection;   

Others  :  1159721
DOI  :  10.1186/1471-2334-12-187

 received in 2012-02-01, accepted in 2012-07-25,  发布年份 2012

【 摘 要 】

Background

Pelvic inflammatory disease (PID) results from the ascending spread of microorganisms from the vagina and endocervix to the upper genital tract. PID can lead to infertility, ectopic pregnancy and chronic pelvic pain. The timing of development of PID after the sexually transmitted bacterial infection Chlamydia trachomatis (chlamydia) might affect the impact of screening interventions, but is currently unknown. This study investigates three hypothetical processes for the timing of progression: at the start, at the end, or throughout the duration of chlamydia infection.

Methods

We develop a compartmental model that describes the trial structure of a published randomised controlled trial (RCT) and allows each of the three processes to be examined using the same model structure. The RCT estimated the effect of a single chlamydia screening test on the cumulative incidence of PID up to one year later. The fraction of chlamydia infected women who progress to PID is obtained for each hypothetical process by the maximum likelihood method using the results of the RCT.

Results

The predicted cumulative incidence of PID cases from all causes after one year depends on the fraction of chlamydia infected women that progresses to PID and on the type of progression. Progression at a constant rate from a chlamydia infection to PID or at the end of the infection was compatible with the findings of the RCT. The corresponding estimated fraction of chlamydia infected women that develops PID is 10% (95% confidence interval 7-13%) in both processes.

Conclusions

The findings of this study suggest that clinical PID can occur throughout the course of a chlamydia infection, which will leave a window of opportunity for screening to prevent PID.

【 授权许可】

   
2012 Herzog et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Centers for Disease Control and Prevention: Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997, 46(RR-10):1-55.
• [2]Paavonen J, Westrom L, Eschenbach D: Pelvic Inflammatory Disease. In Sexually transmitted diseases. 4th edition. Edited by Holmes KK, Sparling PF, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M. New York: McGraw-Hill Medical; 2008:1017-1050.
• [3]Low N, Bender N, Nartey L, Shang A, Stephenson JM: Effectiveness of chlamydia screening: systematic review. Int J Epidemiol 2009, 38:435-448.
• [4]World Health Organization: Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates. Geneva: World Health Organization; 2001.
• [5]Stamm WE: Chlamydia trachomatis Infection of the Adults. In Sexually transmitted diseases. 4th edition. Edited by Holmes KK, Sparling PF, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M. New York: McGraw-Hill Medical; 2008:575-593.
• [6]Althaus CL, Heijne JCM, Roellin A, Low N: Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics 2010, 2:123-131.
• [7]Molano M, Meijer CJLM, Weiderpass E, Arslan A, Posso H, Franceschi S, Ronderos M, Muñoz N, van den Brule AJC: The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005, 191:907-916.
• [8]Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC: Summary: The Natural History and Immunobiology of Chlamydia trachomatis Genital Infection and Implications for Chlamydia Control. J Infect Dis 2010, 201:S190-S204.
• [9]Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE: Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996, 334:1362-1366.
• [10]Ostergaard L, Andersen B, Møller JK, Olesen F: Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 2000, 31:951-957.
• [11]Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, Simms I, Hay P: Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010, 340:c1642.
• [12]Pal S, Hui W, Peterson EM, La Maza LM D: Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. J Med Microbiol 1998, 47:599-605.
• [13]Herzog SA, Heijne JCM, Althaus CL, Low N: Describing progression form Chlamydia trachomatis and Neisseria gonorrhoeae infections to pelvic inflammatory disease: systematic review of mathematical modelling studies. Sex Transm Dis 2012, 39:628-637.
• [14]Oakeshott P, Kerry S, Atherton H, Aghaizu A, Hay S, Taylor-Robinson D, Simms I, Hay P: Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. Trials 2008, 9:73. BioMed Central Full Text
• [15]Burnham KP, Anderson DR: Model selection and multi-model inference: A practical information-theoretic approach. 2nd edition. New York, NY: Springer; 2010.
• [16]Heijne JCM, Althaus CL, Herzog SA, Kretzschmar M, Low N: The role of reinfection and partner notification in the efficacy of chlamydia screening programs. J Infect Dis 2011, 203:372-377.
• [17]Batteiger BE, Tu W, Ofner S, van der Pol B, Stothard DR, Orr DP, Katz BP, Fortenberry JD: Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010, 201:42-51.
• [18]Blower SM, Small PM, Hopewell PC: Control strategies for tuberculosis epidemics: new models for old problems. Science 1996, 273:497-500.
• [19]Wolfram Research Inc: Mathematica Edition. Champaign, Illinois: Wolfram Research Inc; 2008.
• [20]R Development Core Team: R: A Language and Environment for Statistical. 64Bit. Vienna, Austria: R Foundation for Statistical Computing; 2011.
• [21]Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, Simms I, Taylor-Robinson D, Dohn B, Jensen JS: Is Mycoplasma genitalium in women the "New Chlamydia?" A community-based prospective cohort study. Clin Infect Dis 2010, 51:1160-1166.
• [22]Smith KJ, Cook RL, Roberts MS: Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals. Value Health 2007, 10:358-366.
• [23]Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, Bass DC, Sweet RL, Rice P, Richter HE: Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004, 104:761-769.
• [24]Ness RB, Hillier SL, Kip KE, Richter HE, Soper DE, Stamm CA, McGregor JA, Bass DC, Rice P, Sweet RL: Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol 2005, 161:186-195.
• [25]Adams EJ, Turner KME, Edmunds WJ, Roberts TE, Low N: The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Infect 2007, 83:267-275.
• [26]Rank RG, Sanders MM, Patton DL: Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. Sex Transm Dis 1995, 22:48-54.
• [27]Gottlieb SL, Berman SM, Low N: Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis 2010, 201:S156-S167.
• [28]Aghaizu A, Adams EJ, Turner K, Kerry S, Hay P, Simms I, Oakeshott P: What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the Prevention Of Pelvic Infection (POPI) trial. Sex Transm Infect 2011, 87:312-317.
• [29]Heijne JCM, Tao G, Kent CK, Low N: Uptake of regular chlamydia testing by U.S. women: a longitudinal study. Am J Prev Med 2010, 39:243-250.
• [30]National Chlamydia Screening Programme: England Quarters 1–4 April 2010 - March 2011. National Chlamydia Screening Programme. Available at: http://www.chlamydiascreening.nhs.uk/ps/assets/pdfs/data/sha_presentations11/Q1-4%202010-11%20ENGLAND.pdf webcite (accessed 28.06.2011).